Scorpion Capital & MiNK Therapeutics

Scorpion Capital: Scorpion Capital published a critical report on MiNK Therapeutics' drug candidate DCCR, alleging significant concerns regarding its safety, efficacy, and clinical trial data, which led to a decline in MiNK Therapeutics' stock price.

MiNK Therapeutics: MiNK Therapeutics is the primary defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about the safety and commercial viability of its drug candidate, DCCR. The company's stock price has significantly declined following reports of safety concerns, a patient death, and disruptions in DCCR's launch.

Scorpion Capital: Scorpion Capital issued a report on August 15, 2025, which purportedly caused a disruption in DCCR's launch trajectory and revealed significant issues with MiNK Therapeutics' Phase 3 clinical trial program.

MiNK Therapeutics: MiNK Therapeutics is the defendant in a securities fraud class action lawsuit, accused of making materially false and misleading statements regarding its DCCR clinical trial program, which led to a significant stock price decline.